Why would Medutest report 98.4% where the supplier certificate says something higher?

Details up front: Medutest · 98.4%.

Before I write this off, I want to check whether it is a known failure mode.

I have the lot number, the certificate and the date, and I am happy to compare them against anything.

What is the differential here, and which test discriminates between the options?

Start from what the detector sees, because that tells you what the number means.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

What each test answers

The part that matters: column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

If you are ranking vendors, specify a method and have all samples tested at the same place.

To be exact about it, the honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

Specifically, buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

Compare purity within a single laboratory on the same method, never across laboratories.

Worth being precise here: purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

Stated carefully, tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

The relevant detail is that the short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.

If you are ranking vendors, specify a method and have all samples tested at the same place.

Understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."

Compare purity within a single laboratory on the same method, never across laboratories.